HCPCS M1412
Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1/2/3 gene fusion, met ex14 skipping mutation, and ret rearrangement
Current code0 hospitals with prices
What Washington hospitals publish for this code
No Washington hospital publishes a dollar price for this code yet.
Medicare (traditional) reference
CMS publishes no national amount for this code.